CTU: A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

  • Zhang, Alison (Primary Chief Investigator)
  • Contacos, Christine (Clinical Trial Unit Staff)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Chester, Catherine (Clinical Trial Unit Staff)
  • TAIDI, Gina (Clinical Trial Unit Staff)

Project: Research

Project Details

Short title56021927PCR3020
AcronymLibertas
StatusActive
Effective start/end date22/08/23 → 28/06/28